GB9826662D0 - Controlled release formulation - Google Patents

Controlled release formulation

Info

Publication number: GB9826662D0
Authority: GB; United Kingdom
Prior art keywords: controlled release; release formulation; formulation; controlled; release
Prior art date: 1998-12-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

GBGB9826662.0A

Other versions

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ferring BV

Original Assignee

Ferring BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-03

Filing date

1998-12-03

Publication date

1999-01-27

1998-12-03 Application filed by Ferring BV filed Critical Ferring BV

1998-12-03 Priority to GB9826662A priority Critical patent/GB2344287A/en

1999-01-27 Publication of GB9826662D0 publication Critical patent/GB9826662D0/en

1999-12-02 Priority to KR1020017006883A priority patent/KR20010089538A/en

1999-12-02 Priority to CA002353798A priority patent/CA2353798A1/en

1999-12-02 Priority to PCT/GB1999/004045 priority patent/WO2000032218A1/en

1999-12-02 Priority to IL14349699A priority patent/IL143496A0/en

1999-12-02 Priority to HU0104943A priority patent/HUP0104943A3/en

1999-12-02 Priority to TR2001/02273T priority patent/TR200102273T2/en

1999-12-02 Priority to CN99815183A priority patent/CN1332635A/en

1999-12-02 Priority to JP2000584909A priority patent/JP2002531411A/en

1999-12-02 Priority to PL99348575A priority patent/PL348575A1/en

1999-12-02 Priority to AU15732/00A priority patent/AU770676B2/en

1999-12-02 Priority to SK755-2001A priority patent/SK7552001A3/en

1999-12-02 Priority to NZ511984A priority patent/NZ511984A/en

1999-12-02 Priority to EP99958357A priority patent/EP1140133A1/en

1999-12-02 Priority to RU2001118040/15A priority patent/RU2233170C2/en

1999-12-02 Priority to EEP200100293A priority patent/EE200100293A/en

1999-12-02 Priority to BR9915943-0A priority patent/BR9915943A/en

1999-12-02 Priority to CZ20011893A priority patent/CZ20011893A3/en

1999-12-02 Priority to MXPA01005543A priority patent/MXPA01005543A/en

2000-06-07 Publication of GB2344287A publication Critical patent/GB2344287A/en

2001-05-29 Priority to NO20012636A priority patent/NO20012636L/en

2001-06-01 Priority to ZA200104530A priority patent/ZA200104530B/en

2001-06-01 Priority to HR20010421A priority patent/HRP20010421A2/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

GB9826662A 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation Withdrawn GB2344287A (en)

Priority Applications (22)

Application Number	Priority Date	Filing Date	Title
GB9826662A GB2344287A (en)	1998-12-03	1998-12-03	Controlled release pharmaceutical formulation
MXPA01005543A MXPA01005543A (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii.
AU15732/00A AU770676B2 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising GnRH-II
NZ511984A NZ511984A (en)	1998-12-03	1999-12-02	Controlled release formulation comprising GnRH-II
PCT/GB1999/004045 WO2000032218A1 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
IL14349699A IL143496A0 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
HU0104943A HUP0104943A3 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii and its use
TR2001/02273T TR200102273T2 (en)	1998-12-03	1999-12-02	Controlled release formulation containing GNRH-II.
CN99815183A CN1332635A (en)	1998-12-03	1999-12-02	Controlled release formulation comprising GnRH-II
JP2000584909A JP2002531411A (en)	1998-12-03	1999-12-02	Controlled release formulation comprising GNRH-II
PL99348575A PL348575A1 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
KR1020017006883A KR20010089538A (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
SK755-2001A SK7552001A3 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
CA002353798A CA2353798A1 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
EP99958357A EP1140133A1 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
RU2001118040/15A RU2233170C2 (en)	1998-12-03	1999-12-02	Composition with controlled-release comprising gnrh-ii
EEP200100293A EE200100293A (en)	1998-12-03	1999-12-02	Controlled release dosage form containing GnRH-II
BR9915943-0A BR9915943A (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii
CZ20011893A CZ20011893A3 (en)	1998-12-03	1999-12-02	Pharmaceutical preparation, methods for treating health state and use of a peptide
NO20012636A NO20012636L (en)	1998-12-03	2001-05-29	Controlled release formulation comprising GNRH-II
ZA200104530A ZA200104530B (en)	1998-12-03	2001-06-01	Controlled release formulation comprising GNRH-II.
HR20010421A HRP20010421A2 (en)	1998-12-03	2001-06-01	Controlled release formulation comprising gnrh-ii

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9826662A GB2344287A (en)	1998-12-03	1998-12-03	Controlled release pharmaceutical formulation

Publications (2)

Publication Number	Publication Date
GB9826662D0 true GB9826662D0 (en)	1999-01-27
GB2344287A GB2344287A (en)	2000-06-07

Family

ID=10843631

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB9826662A Withdrawn GB2344287A (en)	1998-12-03	1998-12-03	Controlled release pharmaceutical formulation

Country Status (22)

Country	Link
EP (1)	EP1140133A1 (en)
JP (1)	JP2002531411A (en)
KR (1)	KR20010089538A (en)
CN (1)	CN1332635A (en)
AU (1)	AU770676B2 (en)
BR (1)	BR9915943A (en)
CA (1)	CA2353798A1 (en)
CZ (1)	CZ20011893A3 (en)
EE (1)	EE200100293A (en)
GB (1)	GB2344287A (en)
HR (1)	HRP20010421A2 (en)
HU (1)	HUP0104943A3 (en)
IL (1)	IL143496A0 (en)
MX (1)	MXPA01005543A (en)
NO (1)	NO20012636L (en)
NZ (1)	NZ511984A (en)
PL (1)	PL348575A1 (en)
RU (1)	RU2233170C2 (en)
SK (1)	SK7552001A3 (en)
TR (1)	TR200102273T2 (en)
WO (1)	WO2000032218A1 (en)
ZA (1)	ZA200104530B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007012430A1 (en) *	2005-07-26	2007-02-01	Georg-August-Universität-Göttingen	Method for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en)	2006-06-16	2006-09-20	Ardana Bioscience Ltd	Agents, methods and uses
WO2010111617A2 (en)	2009-03-27	2010-09-30	Van Andel Research Institute	Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en)	2009-09-11	2011-03-17	The Board Of Trustees Of The University Of Illinois	Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en)	2009-10-27	2011-05-12	The Board Of Trustees Of The University Of Illinois	Methods of diagnosing diastolic dysfunction
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
US8551946B2 (en)	2010-01-27	2013-10-08	Indiana University Research And Technology Corporation	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
DK2547359T3 (en)	2010-03-15	2016-06-06	The Board Of Trustees Of The Univ Of Illionis	Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
US8940860B2 (en)	2010-06-16	2015-01-27	Indiana University Research And Technology Corporation	Single-chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en)	2010-07-02	2012-01-05	Carsten Gruendker	Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
US9029502B2 (en)	2010-12-20	2015-05-12	The Regents Of The University Of Michigan	Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
NZ612297A (en)	2010-12-22	2015-10-30	Univ Indiana Res & Tech Corp	Glucagon analogs exhibiting gip receptor activity
ME02816B (en)	2011-06-22	2018-01-20	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists
WO2013055791A1 (en)	2011-10-10	2013-04-18	The Regents Of The University Of Michigan	Polymeric nanoparticles for ultrasound imaging and therapy
CN103957927B (en)	2011-11-17	2016-11-09	印第安纳大学研究及科技有限公司	Present the glucagon superfamily peptide of glucocorticoid receptor (GR) activity
WO2013096386A1 (en)	2011-12-20	2013-06-27	Indiana University Research And Technology Corporation	Ctp-based insulin analogs for treatment of diabetes
CA2876706A1 (en)	2012-06-14	2013-12-19	Ambrx, Inc.	Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
DK2864350T3 (en)	2012-06-21	2018-05-28	Univ Indiana Res & Tech Corp	ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY
EP2864351B1 (en)	2012-06-21	2016-08-10	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
EP2900255B1 (en)	2012-09-26	2019-01-30	Indiana University Research and Technology Corporation	Insulin analog dimers
JP6538645B2 (en)	2013-03-14	2019-07-03	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Insulin-incretin complex
US10189908B2 (en)	2014-02-05	2019-01-29	The University Of Chicago	Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CN108271356A (en)	2014-09-24	2018-07-10	印第安纳大学研究及科技有限公司	Duodenin-insulin conjugate
EP3250611B1 (en)	2015-01-26	2021-04-21	The University of Chicago	Car t-cells recognizing cancer-specific il 13r-alpha2
EP3250609A4 (en)	2015-01-26	2018-07-11	The University of Chicago	Il13ra alpha 2 binding agents and use thereof in cancer treatment
CN104789524A (en) *	2015-04-30	2015-07-22	四川大学	Osteoporotic rat primary osteoblasts isolated culture method and application thereof
WO2017024111A1 (en)	2015-08-04	2017-02-09	The University Of Chicago	Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
US11434258B2 (en) *	2017-01-20	2022-09-06	ISR Immune System Regulation Holding AB	Compounds (immunorhelins)
JP2020526483A (en)	2017-06-30	2020-08-31	アムジエン・インコーポレーテツド	How to Treat Heart Failure with Myocardial Node Activator
IL312607A (en)	2017-08-03	2024-07-01	Amgen Inc	Interleukin-21 muteins and methods of treatment
SG11202001499WA (en)	2017-09-08	2020-03-30	Amgen Inc	Inhibitors of kras g12c and methods of using the same
MX2020002921A (en)	2017-09-18	2020-09-28	Univ California	Claudin6 antibodies and methods of treating cancer.
SG11202005605SA (en)	2018-01-12	2020-07-29	Amgen Inc	Anti-pd-1 antibodies and methods of treatment
WO2020055913A1 (en)	2018-09-10	2020-03-19	Cardax, Inc.	Methods of reducing- c-reactive protein and/or treating cardiovascular disease
WO2020191342A1 (en)	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 antibodies and drug conjugates
CN114206934A (en)	2019-03-20	2022-03-18	加利福尼亚大学董事会	Encapsulated protein-6 bispecific antibodies
WO2020196946A1 (en)	2019-03-26	2020-10-01	노벨파마 주식회사	Long-acting fatty acid-binding gnrh derivative and pharmaceutical composition comprising same
EP3952841A1 (en)	2019-04-09	2022-02-16	The Board Of Trustees Of The University Of Illinois	Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en)	2019-04-29	2023-06-22	The Board Of Trustees Of The University Of Illinois	Mek inhibitors for corneal scarring and neovascularization
AU2020266083A1 (en)	2019-04-30	2021-09-23	Instituto de Medicina Molecular João Lobo Antunes	Rank pathway inhibitors in combination with CDK inhibitors
CA3140904A1 (en)	2019-06-24	2020-12-30	Amgen Inc.	Inhibition of sirp-gamma for cancer treatment
JP2022546700A (en)	2019-08-30	2022-11-07	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	Copper-ATSM for the treatment of neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (en)	2020-07-15	2022-05-01	美商安進公司	Tigit and cd112r blockade
CA3208974A1 (en)	2021-01-20	2022-07-28	Bioentre Llc	Ctla4-binding proteins and methods of treating cancer
WO2023137161A1 (en)	2022-01-14	2023-07-20	Amgen Inc.	Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en)	2023-06-27	2024-05-21	Cytokinetics, Incorporated	Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH661206A5 (en) *	1983-09-23	1987-07-15	Debiopharm Sa	PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
DE3414595A1 (en) *	1984-04-18	1985-10-31	Hoechst Ag, 6230 Frankfurt	USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS
US4540513A (en) *	1984-09-25	1985-09-10	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	Decapeptide having gonadotropin releasing activity
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
DE3634435A1 (en) *	1986-10-09	1988-04-14	Hoechst Ag	ANALOGA OF GONADOLIBERIN WITH IMPROVED SOLUBILITY, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE
NO302481B1 (en) *	1990-10-16	1998-03-09	Takeda Chemical Industries Ltd	Polymer for an extended release preparation, as well as an extended release preparation
IT1243390B (en) *	1990-11-22	1994-06-10	Vectorpharma Int	PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2192773C (en) *	1995-12-15	2008-09-23	Hiroaki Okada	Production of sustained-release preparation for injection
WO1997047743A1 (en) *	1996-06-13	1997-12-18	Zymogenetics, Inc.	Human type ii gonadotropin-releasing hormone receptor
US5932547A (en) *	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
GB2343182A (en) *	1998-10-27	2000-05-03	Ferring Bv	Use of GnRH-II and analogues thereof for the treatment of osteoporosis

1998
- 1998-12-03 GB GB9826662A patent/GB2344287A/en not_active Withdrawn
1999
- 1999-12-02 JP JP2000584909A patent/JP2002531411A/en active Pending
- 1999-12-02 SK SK755-2001A patent/SK7552001A3/en unknown
- 1999-12-02 IL IL14349699A patent/IL143496A0/en unknown
- 1999-12-02 MX MXPA01005543A patent/MXPA01005543A/en unknown
- 1999-12-02 EE EEP200100293A patent/EE200100293A/en unknown
- 1999-12-02 PL PL99348575A patent/PL348575A1/en not_active Application Discontinuation
- 1999-12-02 AU AU15732/00A patent/AU770676B2/en not_active Ceased
- 1999-12-02 CA CA002353798A patent/CA2353798A1/en not_active Abandoned
- 1999-12-02 TR TR2001/02273T patent/TR200102273T2/en unknown
- 1999-12-02 CZ CZ20011893A patent/CZ20011893A3/en unknown
- 1999-12-02 HU HU0104943A patent/HUP0104943A3/en unknown
- 1999-12-02 CN CN99815183A patent/CN1332635A/en active Pending
- 1999-12-02 WO PCT/GB1999/004045 patent/WO2000032218A1/en not_active Application Discontinuation
- 1999-12-02 EP EP99958357A patent/EP1140133A1/en not_active Withdrawn
- 1999-12-02 NZ NZ511984A patent/NZ511984A/en unknown
- 1999-12-02 KR KR1020017006883A patent/KR20010089538A/en not_active Application Discontinuation
- 1999-12-02 RU RU2001118040/15A patent/RU2233170C2/en not_active IP Right Cessation
- 1999-12-02 BR BR9915943-0A patent/BR9915943A/en not_active IP Right Cessation
2001
- 2001-05-29 NO NO20012636A patent/NO20012636L/en not_active Application Discontinuation
- 2001-06-01 ZA ZA200104530A patent/ZA200104530B/en unknown
- 2001-06-01 HR HR20010421A patent/HRP20010421A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0104943A2 (en)	2002-06-29
HRP20010421A2 (en)	2002-06-30
CN1332635A (en)	2002-01-23
AU770676B2 (en)	2004-02-26
NO20012636D0 (en)	2001-05-29
EP1140133A1 (en)	2001-10-10
SK7552001A3 (en)	2002-02-05
PL348575A1 (en)	2002-06-03
EE200100293A (en)	2002-08-15
HUP0104943A3 (en)	2002-08-28
MXPA01005543A (en)	2003-07-14
BR9915943A (en)	2001-08-21
IL143496A0 (en)	2002-04-21
JP2002531411A (en)	2002-09-24
KR20010089538A (en)	2001-10-06
NO20012636L (en)	2001-07-12
CZ20011893A3 (en)	2002-05-15
TR200102273T2 (en)	2001-12-21
WO2000032218A1 (en)	2000-06-08
ZA200104530B (en)	2002-06-04
AU1573200A (en)	2000-06-19
CA2353798A1 (en)	2000-06-08
GB2344287A (en)	2000-06-07
RU2233170C2 (en)	2004-07-27
NZ511984A (en)	2002-11-26

Publication	Publication Date	Title
GB9826662D0 (en)	1999-01-27	Controlled release formulation
EG24198A (en)	2008-10-14	Extended release formulation
SG71879A1 (en)	2000-04-18	Controlled release compositions
SG93831A1 (en)	2003-01-21	Polimeric controlled release compositions
GB2339000B (en)	2002-09-25	Release device
EP1107735A4 (en)	2002-05-15	Omeprazole formulation
HUP0203680A3 (en)	2005-01-28	Controlled release hydrocodone formulations
GB9804013D0 (en)	1998-04-22	Formulations
SG71789A1 (en)	2000-04-18	Controlled release compositions
EG24226A (en)	2008-11-10	Formulation
HRP20000213B1 (en)	2004-04-30	Extended release formulation
SG72947A1 (en)	2000-05-23	Controlled release compositions
GB9905898D0 (en)	1999-05-05	Controlled-dose formulation
GB9902304D0 (en)	1999-03-24	Formulation
AUPP279698A0 (en)	1998-04-30	Sustained release formulation
GB2334486B (en)	2002-03-20	Release unit
GB2322867B (en)	2000-10-18	Release agent
GB9810180D0 (en)	1998-07-08	Novel formulation
GB9815002D0 (en)	1998-09-09	Formulations
GB9815001D0 (en)	1998-09-09	Formulations
GB9927614D0 (en)	2000-01-19	Sterliant formulation
GB9711946D0 (en)	1997-08-06	Release devices
GB9816563D0 (en)	1998-09-30	Controlled release formulations
GB9404544D0 (en)	1994-04-20	Controlled release formulation
ZA983505B (en)	1998-10-30	Controlled release pesticidal compositions

Legal Events

Date	Code	Title	Description
2001-03-21	WAP	Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)